These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

414 related articles for article (PubMed ID: 8261581)

  • 21. Combined carboplatin and cisplatin. Limited prospects for dose intensification.
    Waterhouse DM; Reynolds RK; Natale RB
    Cancer; 1993 Jun; 71(12):4060-6. PubMed ID: 8508371
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cisplatin chemoprotection and rescue: pharmacologic modulation of toxicity.
    Gandara DR; Perez EA; Weibe V; De Gregorio MW
    Semin Oncol; 1991 Feb; 18(1 Suppl 3):49-55. PubMed ID: 1848372
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Squalene selectively protects mouse bone marrow progenitors against cisplatin and carboplatin-induced cytotoxicity in vivo without protecting tumor growth.
    Das B; Antoon R; Tsuchida R; Lotfi S; Morozova O; Farhat W; Malkin D; Koren G; Yeger H; Baruchel S
    Neoplasia; 2008 Oct; 10(10):1105-19. PubMed ID: 18813359
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Phase II trial of cisplatin plus WR-2721 (amifostine) for metastatic breast carcinoma: an Eastern Cooperative Oncology Group Study (E8188).
    Gradishar WJ; Stephenson P; Glover DJ; Neuberg DS; Moore MR; Windschitl HE; Piel I; Abeloff MD
    Cancer; 2001 Nov; 92(10):2517-22. PubMed ID: 11745184
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neurologic protection by amifostine.
    DiPaola RS; Schuchter L
    Semin Oncol; 1999 Apr; 26(2 Suppl 7):82-8. PubMed ID: 10348265
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Protection of normal tissue from the cytotoxic effects of chemotherapy and radiation by amifostine: clinical experiences.
    Capizzi RL; Oster W
    Eur J Cancer; 1995; 31A Suppl 1():S8-13. PubMed ID: 7577096
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modulation of platinum-induced toxicities and therapeutic index: mechanistic insights and first- and second-generation protecting agents.
    Hausheer FH; Kanter P; Cao S; Haridas K; Seetharamulu P; Reddy D; Petluru P; Zhao M; Murali D; Saxe JD; Yao S; Martinez N; Zukowski A; Rustum YM
    Semin Oncol; 1998 Oct; 25(5):584-99. PubMed ID: 9783598
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Nephropathy in Patients Undergoing Cancer Drug Therapy - Platinum Derivatives(Cisplatin and Carboplatin)].
    Matsuoka A; Ando Y
    Gan To Kagaku Ryoho; 2017 Mar; 44(3):200-203. PubMed ID: 28292990
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nephrotoxicity after high-dose carboplatin, etoposide and ifosfamide in germ-cell tumors: incidence and implications for hematologic recovery and clinical outcome.
    Beyer J; Rick O; Weinknecht S; Kingreen D; Lenz K; Siegert W
    Bone Marrow Transplant; 1997 Nov; 20(10):813-9. PubMed ID: 9404920
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics of cisplatin with and without amifostine in tumour-bearing nude mice.
    Korst AE; Boven E; van der Sterre ML; Fichtinger-Schepman AM; van der Vijgh WJ
    Eur J Cancer; 1998 Feb; 34(3):412-6. PubMed ID: 9640232
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Meta-analysis of the efficacy of amifostine in the prevention of cisplatin ototoxicity.
    Duval M; Daniel SJ
    J Otolaryngol Head Neck Surg; 2012 Oct; 41(5):309-15. PubMed ID: 23092832
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Amifostine protects against chemotherapy-induced neurotoxicity: an in vitro investigation.
    Verstappen CC; Postma TJ; Geldof AA; Heimans JJ
    Anticancer Res; 2004; 24(4):2337-41. PubMed ID: 15330181
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin.
    Cornelison TL; Reed E
    Gynecol Oncol; 1993 Aug; 50(2):147-58. PubMed ID: 8375728
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of amifostine as a chemoprotectant during high-dose chemotherapy in autologous peripheral blood stem cell transplantation.
    Cronin S; Uberti JP; Ayash LJ; Raith C; Ratanatharathorn V
    Bone Marrow Transplant; 2000 Dec; 26(11):1247-9. PubMed ID: 11149742
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Amifostine and chemotherapy-related thrombocytopenia.
    Budd GT
    Semin Oncol; 1996 Aug; 23(4 Suppl 8):49-52. PubMed ID: 8783667
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Delayed administration of sodium thiosulfate in animal models reduces platinum ototoxicity without reduction of antitumor activity.
    Muldoon LL; Pagel MA; Kroll RA; Brummett RE; Doolittle ND; Zuhowski EG; Egorin MJ; Neuwelt EA
    Clin Cancer Res; 2000 Jan; 6(1):309-15. PubMed ID: 10656463
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cisplatin nephrotoxicity.
    Fillastre JP; Raguenez-Viotte G
    Toxicol Lett; 1989 Mar; 46(1-3):163-75. PubMed ID: 2650023
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical effects of amifostine (Ethyol) in patients treated with carboplatin.
    Budd GT; Ganapathi R; Bukowski RM; Murthy S
    Eur J Cancer; 1996; 32A Suppl 4():S43-5. PubMed ID: 8976822
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Early and late renal adverse effects after potentially nephrotoxic treatment for childhood cancer.
    Knijnenburg SL; Mulder RL; Schouten-Van Meeteren AY; Bökenkamp A; Blufpand H; van Dulmen-den Broeder E; Veening MA; Kremer LC; Jaspers MW
    Cochrane Database Syst Rev; 2013 Oct; (10):CD008944. PubMed ID: 24101439
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A risk-benefit assessment of amifostine in cytoprotection.
    Mabro M; Faivre S; Raymond E
    Drug Saf; 1999 Nov; 21(5):367-87. PubMed ID: 10554052
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.